Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis

Tiziano Barbui, Alessandro M. Vannucchi, Alessandra Carobbio, Jurgen Thiele, Elisa Rumi, Heinz Gisslinger, Francesco Rodeghiero, Maria Luigia Randi, Alessandro Rambaldi, Lisa Pieri, Animesh D Pardanani, Francesco Passamonti, Guido Finazzi, Ayalew Tefferi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.

Original languageEnglish (US)
Pages (from-to)434-437
Number of pages4
JournalAmerican Journal of Hematology
Volume90
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Polycythemia Vera
Thrombosis
Age Distribution
Aspirin
Early Diagnosis
Age Groups
Demography
Clinical Trials
Calendars
Health
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. / Barbui, Tiziano; Vannucchi, Alessandro M.; Carobbio, Alessandra; Thiele, Jurgen; Rumi, Elisa; Gisslinger, Heinz; Rodeghiero, Francesco; Randi, Maria Luigia; Rambaldi, Alessandro; Pieri, Lisa; Pardanani, Animesh D; Passamonti, Francesco; Finazzi, Guido; Tefferi, Ayalew.

In: American Journal of Hematology, Vol. 90, No. 5, 01.05.2015, p. 434-437.

Research output: Contribution to journalArticle

Barbui, T, Vannucchi, AM, Carobbio, A, Thiele, J, Rumi, E, Gisslinger, H, Rodeghiero, F, Randi, ML, Rambaldi, A, Pieri, L, Pardanani, AD, Passamonti, F, Finazzi, G & Tefferi, A 2015, 'Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis', American Journal of Hematology, vol. 90, no. 5, pp. 434-437. https://doi.org/10.1002/ajh.23970
Barbui, Tiziano ; Vannucchi, Alessandro M. ; Carobbio, Alessandra ; Thiele, Jurgen ; Rumi, Elisa ; Gisslinger, Heinz ; Rodeghiero, Francesco ; Randi, Maria Luigia ; Rambaldi, Alessandro ; Pieri, Lisa ; Pardanani, Animesh D ; Passamonti, Francesco ; Finazzi, Guido ; Tefferi, Ayalew. / Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis. In: American Journal of Hematology. 2015 ; Vol. 90, No. 5. pp. 434-437.
@article{67d2448708754f569eee049562e57ba8,
title = "Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis",
abstract = "Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.",
author = "Tiziano Barbui and Vannucchi, {Alessandro M.} and Alessandra Carobbio and Jurgen Thiele and Elisa Rumi and Heinz Gisslinger and Francesco Rodeghiero and Randi, {Maria Luigia} and Alessandro Rambaldi and Lisa Pieri and Pardanani, {Animesh D} and Francesco Passamonti and Guido Finazzi and Ayalew Tefferi",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/ajh.23970",
language = "English (US)",
volume = "90",
pages = "434--437",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis

AU - Barbui, Tiziano

AU - Vannucchi, Alessandro M.

AU - Carobbio, Alessandra

AU - Thiele, Jurgen

AU - Rumi, Elisa

AU - Gisslinger, Heinz

AU - Rodeghiero, Francesco

AU - Randi, Maria Luigia

AU - Rambaldi, Alessandro

AU - Pieri, Lisa

AU - Pardanani, Animesh D

AU - Passamonti, Francesco

AU - Finazzi, Guido

AU - Tefferi, Ayalew

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.

AB - Most studies in polycythemia vera (PV) include patients with both remote and most recent diagnostic periods and are therefore vulnerable to inaccurate interpretation of time-dependent data. We addressed the particular issue by analyzing presenting characteristics and outcome data among 1,545 patients with WHO-defined PV stratified by a diagnosis period of before or after 2005, which coincides with the first description of JAK2V617F as the molecular marker of PV. Patients diagnosed after 2005 displayed lower hemoglobin values (P<0.0001) and older age (P=0.007) at diagnosis; we suggest ease of diagnosis offered by a molecular marker enabled earlier diagnosis and broader application across older age groups that is further enhanced by recent trends in increased attention and health monitoring for the elderly. Post-2005 diagnosed patients were also more or less likely to receive aspirin and cytoreductive therapy, respectively, and, despite their older age distribution, displayed significantly lower risk of thrombosis in high risk disease. Regardless of the contributing factors to the latter phenomenon, our observations underscore the need to reassess current demographics and frequencies of thrombosis in clinical trial designs including thrombosis prevention in PV.

UR - http://www.scopus.com/inward/record.url?scp=84928228394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928228394&partnerID=8YFLogxK

U2 - 10.1002/ajh.23970

DO - 10.1002/ajh.23970

M3 - Article

VL - 90

SP - 434

EP - 437

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 5

ER -